Gene Therapy Start-Up Voyager Therapeutics Impresses with US$845 M Genzyme Deal

By Heather Cartwright

Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)

Published: 6 Mar-2015

DOI: 10.3833/pdr.v2015.i3.2095     ISSN: 1756-7874

Section: Research & Development



Genzyme, a long-time investor in the gene therapy field, has committed to pay Voyager Therapeutics US$100 M upfront to collaborate on the development and commercialisation of the start-up’s pipeline of adeno-associated virus (AAV)-based gene therapies for severe CNS disorders, including Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details